Medtronic‘s PulseSelect became the first pulsed field ablation (PFA) system to win FDA approval for treating atrial fibrillation (AFib) in December 2023. The world’s largest medical device manufacturer achieved that milestone about 15 years after one of its engineers, Mark Stewart, coined the term “pulsed field ablation” in a research paper … [Read more...] about How Medtronic designed the PulseSelect pulsed field ablation system for AFib
Affera
First look: Medtronic’s Sphere-360 pulsed field ablation catheter design has some new tricks
The investigational Medtronic Sphere-360 pulsed field ablation and mapping catheter uses nitinol for a feature that's unique within Medtronic's PFA device portfolio.
Medtronic recently offered a first look at its Sphere-360 pulsed field ablation (PFA) and mapping catheter, an investigational device with some design features that are new for the world's largest device manufacturer.
In an interview with Medical Design & Outsourcing, Tim Laske, VP of research and business development for Medtronic Cardiac … [Read more...] about First look: Medtronic’s Sphere-360 pulsed field ablation catheter design has some new tricks The investigational Medtronic Sphere-360 pulsed field ablation and mapping catheter uses nitinol for a feature that's unique within Medtronic's PFA device portfolio.
Medtronic completes enrollment in pulsed-field ablation catheter trial
Medtronic today announced it completed enrollment and final treatment in the Sphere Per-AF pivotal trial to study Affera's pulsed-field ablation catheter tech. The trial is evaluating the safety and effectiveness of the Sphere-9. The Sphere-9 is a pulsed field (PF) and radio frequency (RF) ablation and high-density mapping catheter. Along with … [Read more...] about Medtronic completes enrollment in pulsed-field ablation catheter trial
Why Affera’s cardiac ablation technology is worth $1B to Medtronic
Affera started in 2014 with a simple goal that paid off when Medtronic (NYSE:MDT) bought the company for up to $1 billion this year. Achieving that goal, however, took some unconventional and sometimes difficult design choices, Affera founder and CEO Doron Harlev said. Newton, Massachusetts–based Affera's system diagnoses, maps and treats … [Read more...] about Why Affera’s cardiac ablation technology is worth $1B to Medtronic
Medtronic to acquire cardiac arrhythmia treatment developer Affera
Medtronic (NYSE:MDT) announced today that it agreed to acquire cardiac mapping and ablation technology developer Affera. Newton, Massachusetts-based Affera designs and manufactures cardiac mapping and navigation systems, as well as catheter-based cardiac ablation technologies, including a differentiated, focal pulsed-field ablation platform for … [Read more...] about Medtronic to acquire cardiac arrhythmia treatment developer Affera
